Prothena Announces Leadership Team Updates
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Business Wire
Chad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functionsHideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity at a large pharmaceutical company to lead a global product development division DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena’s executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki Garren, M.D., Ph.D., will pursue an opportunity at a large pharmaceutical company to lead a global product development division. Prothena will initiate a search for a world-class healthcare leader as our next Chief Medic
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $33.00 to $31.00. They now have a "neutral" rating on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal [Yahoo! Finance]Yahoo! Finance
- Prothena to Participate in Upcoming Healthcare ConferencesBusiness Wire
PRTA
Earnings
- 8/8/24 - Beat
PRTA
Sec Filings
- 10/3/24 - Form 3
- 10/3/24 - Form 4
- 9/27/24 - Form 8-K
- PRTA's page on the SEC website